Compare PEB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | VCEL |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | PEB | VCEL |
|---|---|---|
| Price | $14.11 | $35.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $12.59 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.4M | 661.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | $2.25 | $17.95 |
| P/E Ratio | ★ N/A | $111.56 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $8.56 | $28.95 |
| 52 Week High | $14.23 | $45.97 |
| Indicator | PEB | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 59.16 |
| Support Level | $10.21 | $34.26 |
| Resistance Level | N/A | $38.48 |
| Average True Range (ATR) | 0.34 | 1.36 |
| MACD | 0.11 | 0.40 |
| Stochastic Oscillator | 96.00 | 96.56 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.